Q-omics provides the consensus-scored KIF13B profile across patient tissues and cancer cell-line models. KIF13B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KIF13B is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, KIF13B protein abundance shows 24,406 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where KIF13B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF13B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF13B survival associations across molecular data types. KIF13B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (10) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF13B RNA expression–survival associations across cancer types. High KIF13B expression shows unfavorable associations in LUAD and LGG, but favorable associations in KIRC, UCEC, HNSC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KIF13B RNA expression.
This table summarizes KIF13B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KIF13B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF13B shows lower tumor expression in KIRC, COAD, HNSC, KIRP and LUSC and higher tumor expression in KICH. The KIRC box plot shows higher KIF13B RNA expression in normal versus tumor tissue (log2 FC = −1.385, t-test p < 0.001).
This table shows molecular features associated with KIF13B in patient tissues and cancer cell lines. In patient samples, KIF13B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KIF13B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
